8 clinical trials registered, 3 recruiting. Interventions under study include drug therapy, biologic therapy, procedural interventions, and other interventions. Pipeline includes 5 PHASE2, 3 PHASE1. Research is sponsored by a mix of industry and academic institutions.
55 publications have been identified in PubMed for ovarian carcinosarcoma. Research spans Case Report / Case Series (40%), Basic Science / Preclinical (16%), and Epidemiology / Natural History (13%).
Zhao J (2026). [PMID: 41563443](https://pubmed.ncbi.nlm.nih.gov/41563443/). *Virchows Arch*. [Basic Science / Preclinical]
Abu Shamleh R (2026). [PMID: 42031396](https://pubmed.ncbi.nlm.nih.gov/42031396/). *BMJ Case Rep*. [Case Report / Case Series]
Han J (2026). [PMID: 41611572](https://pubmed.ncbi.nlm.nih.gov/41611572/). *Int J Gynecol Cancer*. [Other]
Hammer PM (2026). [PMID: 41638575](https://pubmed.ncbi.nlm.nih.gov/41638575/). *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*. [Epidemiology / Natural History]
Tashiro A (2026). [PMID: 41943778](https://pubmed.ncbi.nlm.nih.gov/41943778/). *Cureus*. [Basic Science / Preclinical]
Bottazzi S (2026). [PMID: 40704674](https://pubmed.ncbi.nlm.nih.gov/40704674/). *Br J Radiol*. [Review / Meta-Analysis]
Devins KM (2026). [PMID: 41801179](https://pubmed.ncbi.nlm.nih.gov/41801179/). *Am J Surg Pathol*. [Case Report / Case Series]
Abozenah Y (2026). [PMID: 41688255](https://pubmed.ncbi.nlm.nih.gov/41688255/). *Int J Gynecol Cancer*. [Other]
Farrell A (2026). [PMID: 41495830](https://pubmed.ncbi.nlm.nih.gov/41495830/). *Journal of experimental & clinical cancer research : CR*. [Gene Therapy / Novel Therapeutics]
Nakama K (2026). [PMID: 41236858](https://pubmed.ncbi.nlm.nih.gov/41236858/). *Int J Surg Pathol*. [Case Report / Case Series]
